Allinky Biopharma

Allinky Biopharma is a private, preclinical-stage biotech pioneering novel oral allosteric inhibitors for chronic inflammation and cancer. Its core innovation is a first-in-class oral inhibitor targeting the production of IL-1β, a key inflammatory mediator, with significant patents granted in the US, Europe, and China. The company is backed by venture capital and non-dilutive grants, having recently secured a €2M capital increase and a Seal of Excellence from the EU's EIC Accelerator, positioning it to advance its lead candidate towards clinical trials.

Platform for the discovery and development of oral allosteric inhibitors targeting key molecular mediators in chronic inflammation and cancer.

Competes with biologic IL-1 inhibitors (e.g., Novartis's canakinumab) and other companies developing oral anti-inflammatory agents. In oncology, faces competition from numerous biopharma firms pursuing targeted and allosteric kinase inhibitors. Differentiation hinges on proving the superiority of its novel production-inhibition mechanism.